Jim Simons’s Apogee Therapeutics APGE Stock Holding History

Jim Simons’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.5M	Buy	+146,800	New	+$13.2M	0.03%	709
2025 Q3	–	Sell	-41,100	Closed	-$1.78M	–	3481
2025 Q2	$1.78M	Buy	+41,100	New	+$1.56M	﹤0.01%	2181
2024 Q3	–	Sell	-156,204	Closed	-$6.15M	–	3510
2024 Q2	$6.15M	Buy	156,204 +67,504	+76%	+$3.28M	0.01%	1181
2024 Q1	$5.89M	Buy	+88,700	New	+$3.87M	0.01%	1309

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Jim Simons's APGE Position: Q2 2026 in Review

Jim Simons opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 146,800 shares worth $19.5M. The stake represents 0.03% of the portfolio and ranks #709 among its holdings. This is a return to the name: Jim Simons previously reported a position in APGE as recently as Q2 2025.

Jim Simons first reported a position in APGE in Q1 2024 and has held it in 4 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Jim Simons held 146,800 shares of Apogee Therapeutics worth $19.5M as of Q2 2026.
Apogee Therapeutics was a new Jim Simons position in Q2 2026.
Apogee Therapeutics made up 0.03% of Jim Simons's portfolio in Q2 2026, its #709 holding.
Jim Simons first reported a position in Apogee Therapeutics in Q1 2024 and has held it in 4 quarters since.
288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.